Immunome (NASDAQ:IMNM) Sets New 1-Year Low – Time to Sell?

Immunome, Inc. (NASDAQ:IMNM)’s share price reached a new 52-week low on Monday . The company traded as low as $6.41 and last traded at $6.58, with a volume of 94321 shares. The stock had previously closed at $6.99.

Analyst Ratings Changes

Several analysts have issued reports on IMNM shares. Wedbush reaffirmed an “outperform” rating and set a $33.00 target price on shares of Immunome in a research report on Thursday, March 20th. Lifesci Capital initiated coverage on Immunome in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 target price on the stock. Guggenheim decreased their price target on shares of Immunome from $35.00 to $25.00 and set a “buy” rating for the company in a research report on Thursday, March 20th. Finally, Stephens reaffirmed an “overweight” rating and issued a $30.00 price objective on shares of Immunome in a research report on Thursday, March 20th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $25.50.

Immunome Stock Down 7.0 %

The company has a market capitalization of $544.31 million, a PE ratio of -0.77 and a beta of 1.93. The business has a 50 day simple moving average of $9.36 and a 200 day simple moving average of $11.16.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.16). The company had revenue of $2.74 million during the quarter, compared to analysts’ expectations of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. Equities analysts expect that Immunome, Inc. will post -2.21 EPS for the current fiscal year.

Insider Transactions at Immunome

In other news, Director Jean Jacques Bienaime acquired 7,000 shares of Immunome stock in a transaction dated Monday, March 24th. The stock was purchased at an average cost of $8.21 per share, for a total transaction of $57,470.00. Following the completion of the purchase, the director now directly owns 23,615 shares in the company, valued at $193,879.15. This trade represents a 42.13 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Clay B. Siegall bought 150,000 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was purchased at an average price of $7.75 per share, for a total transaction of $1,162,500.00. Following the transaction, the chief executive officer now owns 669,636 shares of the company’s stock, valued at $5,189,679. The trade was a 28.87 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 306,400 shares of company stock worth $2,322,995. Company insiders own 8.60% of the company’s stock.

Hedge Funds Weigh In On Immunome

Institutional investors have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its stake in shares of Immunome by 6.6% in the third quarter. JPMorgan Chase & Co. now owns 24,565 shares of the company’s stock worth $359,000 after acquiring an additional 1,520 shares during the period. Sequoia Financial Advisors LLC grew its position in Immunome by 11.7% during the 4th quarter. Sequoia Financial Advisors LLC now owns 19,065 shares of the company’s stock worth $202,000 after purchasing an additional 2,000 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in shares of Immunome by 5.1% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 41,505 shares of the company’s stock valued at $441,000 after buying an additional 2,005 shares during the last quarter. Intech Investment Management LLC lifted its holdings in shares of Immunome by 26.5% in the 4th quarter. Intech Investment Management LLC now owns 18,961 shares of the company’s stock valued at $201,000 after buying an additional 3,974 shares during the period. Finally, Wellington Management Group LLP grew its holdings in Immunome by 3.5% during the fourth quarter. Wellington Management Group LLP now owns 145,564 shares of the company’s stock worth $1,546,000 after acquiring an additional 4,874 shares during the period. 44.58% of the stock is owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.